Actavis, Forest, their respective directors and certain of their officers and employees may be considered participants in obtaining powers related to the proposed transaction. Information on the persons who, in accordance with the rules of the SEC, may be considered participants at the request of the shareholders of Actavis and Forest in connection with the proposed merger is set out in the joint statement of powers/prospectus common to the SEC. Information about Forest`s directors and officers can be found in the proxy statement for the 2013 Annual General Meeting, filed with the SEC on July 8, 2013, and some of its most recent reports on Form 8-K. Information on Actavis` directors and officers can be found in the proxy statement for the 2013 Annual General Meeting. which, on 29 Additional information about participants in proxy applications and a description of their direct and indirect interests, by holding securities or otherwise, will be included in the joint proxy statement/prospectus filed with the aforementioned registration statement on Form S-4 and in other relevant documents filed with the SEC as they become available. DUBLIN, July 2, 2014 /PRNewswire/ — Actavis plc (NYSE: ACT) today announced the final results of the elections held by the shareholders of Forest Laboratories, Inc. (“Forest”) regarding their preference for the form of merger thinking they would obtain in connection with Actavis` acquisition of Forest. The Commission`s agreement to adopt the approval agreement, which contains the proposal for assent, was 5 to 0. The FTC will soon publish a description of the consent agreement in the federal registry. The agreement will be subject to public comment for 30 days, starting today until 30 July 2014, after which the Commission will decide whether to finalise the proposed approval. Interested parties may submit written comments electronically or in hard copy by following the instructions in the “Invitation to Comment” section of the “Additional Information” section. Comments may be submitted electronically. DUBLIN, Ireland and NEW YORK, Feb.
18, 2014 /PRNewswire/ — Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) announced today that they have entered into a final agreement under which Actavis will acquire Forest for a cash and equity combination valued at approximately $25 billion, or US$89.48 per forest share (26.04 $US in cash and 0.3306 Actavis shares for each forest share). The consideration per share corresponds to a premium of approximately 25 per cent per share to Forest`s share price and a premium of approximately 31 per cent to forest`s 10-day weighted average share price at the close of trading on February 14, 2014. If successfully completed, the transaction will bring together two of the world`s fastest-growing specialty program companies, with annual revenues of more than $15 billion in 2015. For more information, visit the Actavis website in www.actavis.com. This Communication does not constitute an offer to sell, an invitation to issue an offer to buy securities, an invitation to issue a voice or authorization, or a sale of securities in any jurisdiction where such an offer, invitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. As part of the proposed merger between Actavis and Forest, Actavis will file with the Securities and Exchange Commission (the SEC) a registration statement on Form S-4 containing a joint proxy statement from Actavis and Forest, which is also a prospectus of Actavis. . . .